🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

U.S. CDC advisers recommend COVID-19 vaccine for young children

Published 11/02/2021, 07:10 AM
Updated 11/02/2021, 09:15 PM
© Reuters. A medical worker prepares a dose of the "Comirnaty" Pfizer BioNTech COVID-19 vaccine in a vaccination center in Nantes, France, October 6, 2021. REUTERS/Stephane Mahe/Files
PFE
-

By Michael Erman

(Reuters) - Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday unanimously supported broad use of Pfizer (NYSE:PFE) and BioNTech's COVID-19 vaccine in children ages 5 to 11, with shots potentially going into young arms as soon as Wednesday.

They said the benefits of vaccination outweigh the risks of the vaccine. Much of their discussion stemmed from rare cases of heart inflammation that have been linked to the vaccine, particularly young men.

CDC Director Rochelle Walensky must sign off on recommendations before the United States can begin administering the vaccine to children in the age group. The U.S. Food and Drug Administration granted emergency use https://www.reuters.com/world/us/us-fda-expected-authorize-first-covid-19-vaccine-young-children-friday-nyt-2021-10-29 authorization of the vaccine in 5-11 year olds on Friday.

The FDA authorized a 10-microgram dose of Pfizer's vaccine in young children. The original shot given to those age 12 and older is 30 micrograms.

At the outset of the meeting Walensky said that pediatric hospitalizations had surged during the recent wave driven by the Delta variant of the coronavirus.

The risk from COVID-19 "is too high and too devastating to our children and far higher than for many other diseases for which we vaccinate children," she said.

Walensky said school closures have had detrimental social and mental health impacts on children.

"Pediatric vaccination has the power to help us change all of that," she said.

The U.S. government and Pfizer have already begun distributing the vaccine in preparation for a widespread rollout for children, many of whom are back in school for in-person learning.

© Reuters. A medical worker prepares a dose of the

Earlier this week, the White House said the United States has enough supply of the Pfizer/BioNTech vaccine for all 28 million children aged 5 to 11. While some children may be able to get their first shots as soon as Wednesday, the plans is for the U.S. pediatric vaccine program to be running at full strength by next week, a Biden administration official said.

Only a few other countries, including China, Cuba and the United Arab Emirates, have so far cleared COVID-19 vaccines for children in this age group and younger.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.